Showing 6 posts of 6 posts found.

NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic

September 30, 2016
Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo

The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …


NICE recommends Amgen’s Imlygic for advanced skin cancer

August 9, 2016
Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer

NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …


Amgen skin cancer drug Imlygic rejected by NICE

March 16, 2016
Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer

NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …


European approval for Amgen cancer drug Imlygic

December 18, 2015
Sales and Marketing Amgen, European Commission, Imlygic, melanoma, skin cancer, t-vec, talimogene laherparepvec

The European Commission has approved the use of Amgen’s Imlygic for adults with advanced melanoma, making it the first drug …


FDA approves first-in-class Amgen melanoma drug

October 28, 2015
Research and Development, Sales and Marketing Amgen, Imlygic, melonoma

The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …


Amgen skin cancer drug gets European approval

October 23, 2015
Research and Development Amgen, Imlygic, melanoma, skin cancer

Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …

Latest content